Posted by Michael Wonder on 20 Nov 2017
Bayer’s Stivarga wins NICE approval for GIST
20 November 2017 - Bayer’s Stivarga has been recommended by the National Institute for Health and Care Excellence as a treatment for some patients with a gastro-intestinal stromal tumour.
Specifically, the cost watchdog has ruled that the treatment can be routinely funded on the NHS to treat unresectable or metastatic gastro-intestinal stromal tumour in adults whose disease has progressed on, or who are intolerant to, prior treatment with imatinib and sunitinib.
NICE also stipulates that the recommendation only stands if patients have an Eastern Cooperative Oncology Group performance status is 0 to 1, and the company provides Stivarga (regorafenib) with the discount agreed in the confidential patient access scheme.
